Biogen, a large-cap Biotechnology stock, moved 0.8% this afternoon. Here are some facts about the company that we're keeping an eye on:
-
Biogen has logged a -13.8% 52 week change, compared to 16.2% for the S&P 500
-
BIIB has an average analyst rating of buy and is -21.67% away from its mean target price of $320.47 per share
-
Its trailing earnings per share (EPS) is $10.06, which brings its trailing Price to Earnings (P/E) ratio to 25.0. The Health Care sector's average P/E ratio is 30.21
-
The company's forward earnings per share (EPS) is $15.68 and its forward P/E ratio is 16.0
-
The company has a Price to Book (P/B) ratio of 2.51 in contrast to the Health Care sector's average P/B ratio is 4.08
-
The company's free cash flow for the last fiscal year was $1.06 Billion and the average free cash flow growth rate is -27.8%
-
Biogen's revenues have an average growth rate of -6.2% with operating expenses growing at 0.1%. The company's current operating margins stand at 16.1%